Objective To investigate the clinical effect of Bulleyaconitine A Tablets combined with Lidocaine Cataplasms in treatment of postherpetic neuralgia.Methods A total of 156 patients with postherpetic neuralgia admitted to the First Affiliated Hospital of Henan University of Science and Technology from April 2022 to December 2023 were selected and divided into control group and treatment group according to random number table method,with 78 cases in each group.Patients in control group were given Lidocaine Cataplasms,the paste was cut according to the pain area of the patient,and≤3 patches were applied at the same time,and the application time within 24 h was controlled to≤12 h.Patients in the treatment group were po administered with Bulleyaconitine A Tablets on the basis of control group,1 tablet/time,3 times daily.Both groups were treated for 4 weeks.The clinical efficacy of two groups was observed.The visual analogue scale(VAS)scores before treatment and 2 and 4 weeks of treatment,and Sleep disturbance Rating Scale(SDRS),simple depression-anxiety-stress Scale(DASS-21)scores,36-item health survey summary form(SF-36)scores,serum β-endorphin(β-EP)and cyclooxygenase-2(COX-2),interleukin-6(IL-6),and neuron-specific enolase(NSE)in two groups before and after treatment were compared.Results After treatment,the total effective rate of the treatment group was 94.87%,which was significantly higher than that of the control group(84.62%,P<0.05).Pain VAS scores in two groups after 2 and 4 weeks of treatment were lower than those before treatment(P<0.05),and the VAS scores of the treatment groups were lower than those of the control group after 2 and 4 weeks of treatment(P<0.05).After treatment,SDRS and DASS-21 scores in 2 groups were lower than those before treatment,but SF-36 scores were significantly increased(P<0.05).After treatment:SDRS and DASS-21 scores in treatment group were lower than those in control group,but SF-36 scores were higher than those in the control group(P<0.05).After treatment,serum β-EP levels in two groups were significantly increased,but serum COX-2,IL-6,and NSE levels were lower than those before treatment(P<0.05).After treatment,the levels of β-EP,COX-2,IL-6,and NSE in treatment group were better than those in control group(P<0.05).Conclusion Bulleyaconitine A Tablets combined with Lidocaine Cataplasms has good efficacy and safety in treatment of postherpetic neuralgia,and can effectively reduce the degree of pain,improve the sleep quality,emotional state and life quality of patients,which can inhibit neuroinflammation and nerve damage.
Bulleyaconitine A TabletsLidocaine Cataplasmspostherpetic neuralgiaVAS scoreSDRSscoreDASS-21β-EPNSE
万方数据
